# CURRICULUM VITAE – FILIPPO GALLI

## Educazione

*Ottobre 2015:* Ph.D. presso University Medical Centre Groningen (UMCG), Groningen, The Netherlands. In affiliazione con la Nuclear Medicine Unit, Faculty of Medicine and Psychology, Department of Medical-Surgical Sciences and Translational Medicine, "Sapienza" University. Titolo della tesi: Imaging of tumor specific antigens and microenvironment.

*Gennaio-Dicembre 2012:* Master di II livello in "Scienza e tecnologia dei radiofarmaci", 110 cum Laude, Facoltà di Farmacia, Università di Roma "Sapienza".

*Ottobre 2010:* Laurea magistrale in "Biotecnologie mediche, cellular e molcolari" 110 cum Laude. Facoltà di Farmacia e medicina, Università di Roma "Sapienza".

*Ottobre 2007:* Laurea triennale in Biotecnologie, 107/110. Facoltà di Scienze Matematiche, fisiche e naturali, Università di Roma "Tor Vergata".

## Attività di ricerca

*Marzo 2013 - Present:* Assegnista di ricerca in Medicina Nucleare. Presso la medicina nucleare, Facoltà di Medicina e Psicologia, Dipartimento di Scienze Medico-Chirurgiche e di Medicina Traslazionale, Università di Roma "La Sapienza".

*Aprile 2013:* Contratto di consulenza con la Mayo Clinic (Rochester, MN, USA) nel progetto: "Interleukin 2 imaging as a guide to cancer immunotherapy (Ipilimumab) in advanced melanoma: a pilot study".

*Gennaio 2011 – Ottobre 2015:* Studente Ph.D. presso la medicina nucleare, Facoltà di Medicina e Psicologia, Dipartimento di Scienze Medico-Chirurgiche e di Medicina Traslazionale, Università di Roma "La Sapienza". Coinvolto in progetti di marcatura di anticorpi monoclonali ed analoghi di ormoni per l'imaging di processi flogistici e/o oncologici.

*Gennaio 2008 – Ottobre 2010:* Attività di ricerca per tesi di laurea magistrale presso il laboratorio del Prof. A. medicina nucleare, Azienda Ospedaliera S. Andrea: Tesi di laurea nello sviluppo di un nuovo superanalogo per l'imaging del cancro tiroideo scarsamente differenziato.

*Gennaio 2006 – 2007:* Stage e tesi presso il laboratorio di microbiolgia della Prof. P. Ghelardini – Università di Roma "Tor Vergata": attività di ricerca nella visualizzazione del mismatch repair nei batteri.

## Premi, Fellowships & Progetti di ricerca

*Giugno 2016:* Editors' Choice Award per uno dei migliori 3 paper di basic science pubblicato sul The Journal of Nuclear Medicine nel 2015, dal titolo: "In Vivo Imaging of Natural Killer Cell Trafficking in Tumors"

*Luglio 2015:* P.I nel progetto di ateneo "Sapienza": "Comparison between radiolabelled human superagonist TSH analogues TR1401 and TR1402 for in vivo imaging of poorly differentiated thyroid cancer".

*Agosto 2014*: Miglior giovane presentatore al 22th Meeting of the International Research group in

Immuno-Scintigraphy and Therapy (IRIST), Cancun, Mexico.

*Luglio 2014:* P.I. nel progetto di ateneo "Sapienza": Radiolabelling and in vitro studies with a novel anti- CD56 monoclonal antibody for NK cell targeting

*Luglio 2013*: P.I. nel progetto di ateneo "Sapienza": Radiolabelled VEGF Analogues For Diagnostic
Purposes In Ovarian And Thyroid Cancer.

*Novembre 2012:* Miglior giovane presentatore al 21th Meeting of the International Research group in Immuno-Scintigraphy and Therapy (IRIST), Bertinoro, Italy.

*Febbraio 2009*: vincitore di borsa di studio della comunità Europea nell'iniziativa COST-BM0607 per attività di ricerca presso il dipartimento di Radiofarmacia del Prof. H. Maecke ed il dipartimento di malattie infettive del dr. A. Trampuz, Universitatsspital Basel (Svizzera).

**Publications – Filippo Galli, PhD**


1. Varani M, Auletta S, Signore A, Galli F. State of the Art of Natural Killer Cell Imaging: A Systematic Review. Cancers (Basel). 2019 Jul 9;11(7). pii: E967.

2. Anzola LK, Rivera JN, Dierckx RA, Lauri C, Valabrega S, Galli F, Moreno Lopez S, Glaudemans AWJM, Signore A. Value of Somatostatin Receptor Scintigraphy with (99m)Tc-HYNIC-TOC in Patients with Primary Sjögren Syndrome. J Clin Med. 2019 May 30;8(6). pii: E763.

3. Signore A, Lauri C, Auletta S, Anzola K, Galli F, Casali M, Versari A, Glaudemans AWJM. Immuno-Imaging to Predict Treatment Response in Infection, Inflammation and Oncology. J Clin Med. 2019 May 14;8(5). pii: E681.

4. Auletta S, Riolo D, Varani M, Lauri C, Galli F, Signore A. Labelling and Clinical Performance of Human Leukocytes Labelled with (99m)Tc-HMPAO Using Leukokit® with Gelofusine versus Leukokit® with HES as Sedimentation Agent. Contrast Media Mol Imaging. 2019 Mar 25;2019:4368342.

5. Auletta S, Varani M, Horvat R, Galli F, Signore A, Hess S. PET Radiopharmaceuticals for Specific Bacteria Imaging: A Systematic Review. J Clin Med. 2019 Feb 6;8(2). pii: E197.

6. Auletta S, Iodice V, Galli F, Lepareur N, Devillers A, Signore A. Study of Binding Kinetics and Specificity of 99mTc-SSS-Complex and 99mTc-HMPAO to Blood Cells. Contrast Media Mol Imaging. 2018 Oct 25;2018:5603902. eCollection 2018.

7. Markovic SN, Galli F, Suman VJ, Nevala WK, Paulsen AM, Hung JC, Gansen DN, Erickson LA, Marchetti P, Wiseman GA, Signore A. Non-invasive visualization of tumor infiltrating lymphocytes in patients with metastatic melanoma undergoing immune checkpoint inhibitor therapy: a pilot study. Oncotarget. 2018 - 13;9(54):30268-30278.

8. Jamar F, Versari A, Galli F, Lecouvet F, Signore A.Molecular Imaging of Inflammatory Arthritis and Related Disorders. Semin Nucl Med. 2018 May;48(3):277-290. doi: 10.1053/j.semnuclmed.2017.12.005. Epub 2018 Jan 10.

9. Signore A, Anzola KL, Auletta S, Varani M, Petitti A, Pacilio M, Galli F, Lauri C. Current status of molecular imaging in inflammatory and autoimmune disorders. Curr Pharm Des. 2018 Jan 29.

10. Zeelen C, Paus C, Draper D, Heskamp S, Signore A, Galli F, Griessinger CM, Aarntzen EH. In vivo imaging of tumor-infiltrating immune cells: implications for cancer immunotherapy. Q J Nucl Med Mol Imaging. 2018;62:56-77.

11. Auletta S, Baldoni D, Varani M, Galli F, Hajar IA, Duatti A, Ferro-Flores G, Trampuz A, Signore A. Comparison of 99mTc-UBI 29-41, 99mTc-Ciprofloxacin, 99mTc-Ciprofloxacin dithiocarbamate and 111In-biotin for targeting experimental Staphylococcus aureus and Escherichia coli foreign-body infections: an ex-vivo study. Q J Nucl Med Mol Imaging. 2017.

12. Galli F, Artico M, Taurone S, Manni I, Bianchi E, Piaggio G, Weintraub BD, Szkudlinski MW, Agostinelli E, Dierckx RAJO, Signore A. Radiolabeling of VEGF165 with 99mTc to evaluate VEGFR expression in tumor angiogenesis. Int J Oncol. 2017 May 8.

13. Auletta S, Galli F, Lauri C, Martinelli D, Santino I, Signore A.Imaging bacteria with radiolabelled quinolones, cephalosporins and siderophores for imaging infection: a systematic review. Clin Transl Imaging. 2016;4:229-252.

14. Taurone S, Galli F, Signore A, Agostinelli E, Dierckx RA, Minni A, Pucci M, Artico M.VEGF in nuclear medicine: Clinical application in cancer and future perspectives (Review). Int J Oncol. 2016 Aug;49(2):437-47.

15. Anzola-Fuentes LK, Chianelli M, Galli F, Glaudemans AW, Martin Martin L, Todino V, Migliore A, Signore A. Somatostatin receptor scintigraphy in patients with rheumatoid arthritis and secondary Sjögren's syndrome treated with Infliximab: a pilot study. EJNMMI Res. 2016 Dec;6(1):49.

16. Accardo A, Galli F, Mansi R, Del Pozzo L, Aurilio M, Morisco A, Ringhieri P, Signore A, Morelli G, Aloj L. Preclinical evaluation of eight DOTA coupled gastrin-releasing peptide receptor (GRP-R) ligands for in vivo targeting of receptor-expressing tumors. EJNMMI Res. 2016 Dec;6(1):17.

17. Galli F, Rapisarda AS, Stabile H, Manni I, Bonanno E, Piaggio G, Gismondi A, Santoni A, Signore A. In vivo imaging of NK cell trafficking in tumors. J Nucl Med. 2015 Oct;56(10):1575-80.

18. Ceccarelli F, Perricone C, Galli F, Valesini G, Conti F. Use of 99mTc-labelled Anti-TNF Monoclonal Antibodies to Assess Patients Affected by Inflammatory Arthropathies. Int J Radiol Med Imag 2015, 1: 102.

19. Signore A, Glaudemans AW, Galli F, Rouzet F. Imaging infection and inflammation. Biomed Res Int. 2015;2015:615150.

20. Galli F, Lanzolla T, Pietrangeli V, Malviya G, Ricci A, Bruno P, Ragni P, Scopinaro F, Mariotta S, Signore A. In vivo evaluation of TNF-alpha in the lungs of patients affected by sarcoidosis. Biomed Res Int. 2015;2015:401341.

21. Baldoni D, Waibel R, Bläuenstein P, Galli F, Iodice V, Signore A, Schibli R, Trampuz A. Evaluation of a Novel Tc-99m Labelled Vitamin B12 Derivative for Targeting Escherichia coli and Staphylococcus aureus In Vitro and in an Experimental Foreign-Body Infection Model. Mol Imaging Biol. 2015 Apr 10.

22. Galli F, Iodice V, Lauri C, Signore A. New approaches to image thyroid cancer cells and microenvironment. Q J Nucl Med Mol Imaging. 2015;59(2):184-96.

23. Lauri C, Di Traglia S, Galli F, Pizzichini P, Signore A. Current status of PET imaging of differentiated thyroid cancer with second generation radiopharmaceuticals. Q J Nucl Med Mol Imaging. 2015;59(1):105-15.

24. Signore A, Capriotti G, Chianelli M, Bonanno E, Galli F, Catalano C, Quintero AM, De Toma G, Manfrini S, Pozzilli P; Action LADA Group. Detection of insulitis by pancreatic scintigraphy with 99mTc-labeled IL-2 and MRI in patients with LADA (Action LADA 10). Diabetes Care. 2015;38(4):652-8.

25. Malviya G, Galli F, Sonni I, Signore A.Imaging T-lymphocytes in inflammatory diseases: a nuclear medicine approach. Q J Nucl Med Mol Imaging. 2014;58(3):237-57.

26. Galli F, Histed S, Aras O. NK cell imaging by in vitro and in vivo labelling approaches. Q J Nucl Med Mol Imaging. 2014;58(3):276-83.

27. Galli F, Manni I, Piaggio G, Balogh L, Weintraub BD, Szkudlinski MW, Fremont V, Dierckx RA, Signore A. 99mTc labelled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer. Thyroid. 2014 24(8):1297-308.

28. Glaudemans AW, Bonanno E, Galli F, Zeebregts CJ, de Vries EF, Koole M, Luurtsema G, Boersma HH, Taurino M, Slart RH, Signore A. In vivo and in vitro evidence that 99mTc-HYNIC-interleukin-2 is able to detect T lymphocytes in vulnerable atherosclerotic plaques of the carotid artery. Eur J Nucl Med Mol Imaging. 2014; 41(9):1710-9.

29. Erba PA, Glaudemans AW, Veltman NC, Sollini M, Pacilio M, Galli F, Dierckx RA, Signore A. Image acquisition and interpretation criteria for (99m)Tc-HMPAO-labelled white blood cell scintigraphy: results of a multicentre study. Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):615-23.

30. Signore A, Lauri C, Galli F. Radiolabelled probes targeting infection and inflammation for personalized medicine. Curr Pharm Des. 2014;20(14):2338-45.

31. Glaudemans AW, de Vries EF, Galli F, Dierckx RA, Slart RH, Signore A. The use of (18)F-FDG-PET/CT for diagnosis and treatment monitoring of inflammatory and infectious diseases. Clin Dev Immunol. 2013;2013:623036.

32. Glaudemans A.W.J.M, Galli F, Pacilio M, Signore A. Leukocyte and bacteria imaging in prosthetic joint infection. Eur Cells Mater 2013; 25:61-77

33. Karczmarczyk U, Garnuszek P, Maurin M, Di Gialleonardo V, Galli F, Signore A, Mikołajczak R. Investigation of 99mTc-labelling of recombinant human interleukin-2 (rhIL-2) via hydrazinonicotinamide (HYNIC). Nucl Med Biol. 2010;37:795-803.

34. Malviya G, Galli F, Sonni I, Pacilio M, Signore A. Targeting T and B lymphocytes with radiolabelled antibodies for diagnostic and therapeutic applications. Q J Nucl Med Mol Imaging. 2010;54:654-76.

35. Chianelli M, Boerman O C, Malviya G, Galli F, Oyen W J G, Signore A. Receptor binding ligands to image infection. Curr Pharm Des. 2008;14:3316-3325

**Books & Chapters**

1. Galli F. (2020) Gamma Camera Imaging of Infectious Diseases. In: Signore A., Glaudemans A. (eds) Nuclear Medicine in Infectious Diseases. Springer, Cham.

2. Galli F. Imaging of tumor specific antigens and microenvironment. ISBN: 978-90-367-8175-6.

3. Signore A, de Vries EFJ, Galli F and Malviya G. Chapter 22: Applications of molecular small-animal imaging in inflammation and infection. Molecular Imaging of Small Animals: Instrumentation and Applications, 9781493908943 pp. 637 - 683.